Northwestern Mutual Wealth Management Company »

Aileron Therapeutics shares owned by Northwestern Mutual Wealth Management Company

Quarter-by-quarter ownership of Aileron Therapeutics (RNTX) shares owned by Northwestern Mutual Wealth Management Company from 13F filings

Historical chart of Northwestern Mutual Wealth Management Company investment in Aileron Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Aileron Therapeutics held by Northwestern Mutual Wealth Management Company consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aileron Therapeutics by Northwestern Mutual Wealth Management Company

Quarter filed Position value Share count Share price at filing
2025-09-30 $49k 42k 1.15
2025-06-30 $68k 49k 1.40
2025-03-31 $27k 15k 1.77

More positions owned by Northwestern Mutual Wealth Management Company

Ishares Tr Core S&p500 Etf (IVV)
Vanguard Bd Index Fds Total Bnd Mrkt (BND)
Ishares Tr Core S&p Mcp Etf (IJH)
Schwab Strategic Tr Intl Eqty Etf (SCHF)
Ishares Tr Core S&p Scp Etf (IJR)
Invesco Exchange Traded Fd T S&p500 Eql Wgt (RSP)
Fidelity Merrimack Str Tr Total Bd Etf (FBND)
Vanguard Intl Equity Index F Ftse Emr Mkt Etf (VWO)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Ishares Tr 20 Yr Tr Bd Etf (TLT)
Vanguard Tax-managed Fds Van Ftse Dev Mkt (VEA)
Ishares Tr Core Msci Eafe (IEFA)
Ishares Tr Msci Usa Value (VLUE)
Ishares Tr Msci Intl Qualty (IQLT)
Invesco Qqq Tr Unit Ser 1 (QQQ)

View all positions for Northwestern Mutual Wealth Management Company

Top funds holding Aileron Therapeutics

Voss Capital
BIOS Capital Management
Vanguard Group
Prosight Management
University of Texas Investment Management Company
Cable Car Capital
Sigma Planning
Geode Capital Management
Rima Management
Gagnon Securities
BlackRock
Northwestern Mutual Wealth Management Company
Chicago Partners Investment
Susquehanna International
Burns Wealth Management

View all funds holding Aileron Therapeutics